A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
Active Date:
October 01, 2020
IRB Number:
NAPOLI3
Condition/Disease:
Pancreatic Cancer
Lead Researcher:
Alexander Hantel, MD
Location:
Edward Cancer Center - Naperville
Purpose:
The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.
Sponsor: Ipsen
https://clinicaltrials.gov/ct2/show/NCT04083235
Eligibility:
Adenocarcinoma of the pancreas that has not been previously treated in the metastatic setting.
One or more metastatic tumors measurable by CT or MRI.
No prior treatment of pancreatic cancer in the metastatic setting with surgery, radiotherapy, chemotherapy or investigational therapy
Must be metastatic disease.
No history of any second malignancy in the last 2 years
No neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
Status:
Pending IRB Approval for Recruiting
Current Trial Type:
Interventional
Contact Name:
Amanda Keller, BSN
Phone:
630-646-6021
Fax:
630-646-6110
Alternate Phone:
630-646-6072